Heart disease kills more American women than every cancer combined. The risk accelerates sharply at menopause. For more than two decades, women were warned away from the one intervention that could have protected them. In November 2025, the FDA reversed course. Here is what the actual research shows about hormone therapy and women’s cardiovascular health, and why timing is everything.
The most dangerous conversation in women’s medicine right now is the one that does not happen. A woman in her late forties or early fifties walks into her annual checkup. Her blood pressure has crept up. Her LDL is climbing. She has noticed weight gathering around her midsection in a way that diet and exercise no longer touch. Her doctor tells her this is normal at her age, prescribes a statin or makes a vague gesture toward lifestyle, and the visit ends. Nobody mentions menopause. Nobody mentions hormones. Nobody mentions what is actually happening to her cardiovascular system.
Heart disease kills more than 400,000 American women every year. It is the leading cause of death in women over 40, more deadly than all cancers combined. The risk accelerates sharply at menopause as the estrogen that has been protecting her cardiovascular system since adolescence drops to less than ten percent of premenopausal levels. And awareness of all this has been declining, not improving, for fifteen years.
There is a reason for the silence. In 2002, the Women’s Health Initiative trial was halted early because of adverse cardiovascular findings in women on combined hormone therapy. The headlines were everywhere. Hormone therapy prescriptions dropped by nearly 80 percent. Two decades of research since then have substantially revised that picture. The FDA finally caught up in November 2025. Most women, and most of their providers, have not.
Key Takeaways
- Cardiovascular disease is the leading cause of death in women, claiming roughly 400,000 American women per year. Risk rises sharply at menopause as estrogen-mediated cardiovascular protection is lost.
- The “timing hypothesis,” supported by the ELITE trial (NEJM), the KEEPS trial, the Danish Osteoporosis Prevention Study, and stratified re-analyses of the WHI, shows that hormone therapy started within ten years of menopause onset or before age 60 reduces cardiovascular risk. Started after that window, the same therapy can increase risk.
- On November 10, 2025, the FDA removed the black box warnings on cardiovascular disease, breast cancer, and probable dementia from menopause hormone therapy products. The agency explicitly stated the original warnings were based on outdated science and had discouraged appropriate use.
- Comprehensive cardiovascular risk assessment in midlife includes more than the standard lipid panel. ASCVD calculator score, visceral adipose tissue measurement (which DEXA can quantify), inflammatory markers, blood pressure, and family history together determine whether hormone therapy is appropriate.
- At Revitalize Medical Solutions in Sandy, Utah, every woman entering our hormone optimization program receives a comprehensive cardiovascular workup before treatment starts, including DEXA-measured visceral fat, advanced lipid panel, inflammatory markers, and 10-year ASCVD risk calculation. The protocol is built around the window of opportunity, not around it.
Contents
1. What happens to cardiovascular risk at menopause
Before menopause, women have lower rates of cardiovascular disease than men of the same age. This is one of the most consistent observations in cardiovascular epidemiology. After menopause, that gap closes quickly. By her mid-sixties, a woman’s cardiovascular risk profile resembles a man’s of similar age and health status. The protective effect that came with reproductive-age estrogen levels disappears.
What changes during the menopause transition is not subtle. LDL cholesterol rises. HDL cholesterol falls or shifts toward less protective subtypes. Triglycerides climb. Blood pressure tends to creep upward. Insulin sensitivity declines. Visceral adipose tissue, the metabolically active fat that accumulates around abdominal organs, increases substantially even in women whose total body weight stays the same. Inflammatory markers including hs-CRP rise. Each of these changes is an independent cardiovascular risk factor. They all happen together, driven by the same underlying hormonal shift.
The American Heart Association’s 2020 scientific statement on Menopause Transition and Cardiovascular Disease Risk made the case explicitly: the menopause transition itself contributes to the increase in coronary heart disease risk that women experience in midlife. It is not just aging. It is a specific physiological shift with specific cardiovascular consequences.
And yet awareness has been declining. The most recent AHA national survey found that awareness that heart disease is the leading cause of death in women actually fell between 2009 and 2019, particularly among Black, Hispanic, and younger women. Most women still believe breast cancer is the bigger threat. The numbers do not support that belief.
Key insight: Cardiovascular disease kills more American women annually than every cancer combined. The menopause transition is when the risk profile changes most dramatically, and it is also the moment when women are least likely to be receiving cardiovascular-protective care.
2. Why estrogen protects the heart
Estrogen acts on the cardiovascular system through several distinct mechanisms, which is part of why losing it has such broad effects.
Endothelial function. The endothelium is the single-cell layer that lines every blood vessel in the body. It is not just plumbing. It is an active, signaling tissue that controls vasodilation, inflammation, and clot formation. Estrogen supports endothelial nitric oxide production, which keeps blood vessels flexible and dilated. When estrogen drops, endothelial function declines. This is one of the earliest measurable changes in postmenopausal cardiovascular biology.
Lipid metabolism. Estrogen up-regulates LDL receptors in the liver, which clears LDL cholesterol from circulation. It also supports HDL function and influences triglyceride processing. When estrogen drops, LDL rises, HDL function deteriorates, and lipid particle sizes shift toward more atherogenic patterns. Standard lipid panels often miss these shifts because they measure total cholesterol rather than particle number and size.
Visceral fat distribution. Premenopausal women preferentially store fat subcutaneously, in the hips and thighs. Postmenopausal women shift toward visceral storage, around abdominal organs. Visceral adipose tissue is metabolically active in a way subcutaneous fat is not. It produces inflammatory cytokines, contributes to insulin resistance, and is independently associated with cardiovascular risk. A woman can have a normal BMI and still carry dangerous visceral fat loads, which is why measurement matters. DEXA can quantify visceral fat directly.
Inflammation. Chronic low-grade inflammation is one of the strongest predictors of cardiovascular events. Estrogen has anti-inflammatory effects across multiple systems. When estrogen drops, baseline inflammatory markers including hs-CRP tend to rise.
Insulin sensitivity. Estrogen supports insulin signaling in muscle and liver tissue. Postmenopausal insulin resistance is a well-documented phenomenon and is part of why type 2 diabetes incidence rises during the menopause transition.
When you put these mechanisms together, you see why losing ovarian hormone production has such a broad cardiovascular footprint. It is not one risk factor changing. It is the entire metabolic and vascular regulatory system shifting at once.
“The menopause transition is not a slow drift toward cardiovascular risk. It is a phase change. The same woman is in a fundamentally different cardiovascular environment after her last menstrual period than she was a decade earlier.” Nicole Kelly, PA-C, Medical Director
3. The timing hypothesis and what changed at the FDA
To understand why most women have been steered away from hormone therapy for the past 20 years, you have to understand the Women’s Health Initiative. In 2002, the WHI’s combined estrogen-progestin arm was halted early because of an increase in adverse cardiovascular events. The press coverage was immediate and absolute. Hormone therapy was branded as cardiovascular poison. Prescriptions dropped by roughly 80 percent within a year.
What the headlines missed: the average age of women enrolled in the WHI was 63. Most participants were more than ten years past menopause when they started hormone therapy. The trial was not designed to test cardiovascular benefit in younger, recently menopausal women. It was designed to test prevention in an older population that, in retrospect, was the wrong group to demonstrate that benefit. When the WHI data was later re-analyzed stratified by age and time since menopause, a different picture emerged.
In women aged 50 to 59 starting hormone therapy within ten years of menopause onset, the WHI showed reduced coronary heart disease risk, with hazard ratios of 0.76 for combined estrogen-progestin therapy and 0.59 for estrogen-only therapy. Coronary artery calcium, a marker of subclinical atherosclerosis, was significantly lower at 8.7-year follow-up in women who had received estrogen-only therapy compared to placebo. The cardiovascular harm signal that had panicked clinicians in 2002 was concentrated in older women started long after menopause.
This pattern led researchers to formulate what became known as the timing hypothesis or window of opportunity. Hormone therapy initiated during the early postmenopausal years, before significant atherosclerotic plaque has formed, supports the endothelium and reduces cardiovascular risk. Hormone therapy initiated after that window, when plaque is already established, can destabilize existing disease and increase cardiovascular events.
Two subsequent randomized trials were designed specifically to test this hypothesis. The Kronos Early Estrogen Prevention Study (KEEPS) enrolled women within three years of menopause onset and excluded those with known atherosclerosis. The Early Versus Late Intervention Trial with Estradiol (ELITE), published in the New England Journal of Medicine, stratified women into early (within 6 years of menopause) and late (10+ years past menopause) groups and measured atherosclerosis progression directly. ELITE found that hormone therapy slowed atherosclerosis progression in the early group and had no effect in the late group. The timing hypothesis was confirmed.
By 2024, the cardiovascular evidence supporting hormone therapy initiated in the right window was overwhelming. The Endocrine Society and the Menopause Society had both updated their guidelines to reflect this. Most providers had not.
In November 2025, the FDA finally acted. The agency removed the longstanding black box warnings on cardiovascular disease, breast cancer, and probable dementia from menopause hormone therapy products. FDA Commissioner Marty Makary, announcing the decision in JAMA, stated the original warnings were based on outdated science and had discouraged appropriate use of hormone therapy. The action followed a comprehensive scientific review, an expert panel, and a public comment period. The endometrial cancer warning for estrogen-alone products remains in place. Everything else came off.
Key insight: The FDA’s November 2025 decision did not introduce new science. It caught the regulatory framework up to evidence that has been accumulating for two decades. For women in the early postmenopausal window, hormone therapy is now formally recognized as appropriate for cardiovascular risk reduction, not just symptom management.
4. What this looks like in our Sandy, Utah office
Every woman entering our hormone optimization program at our Sandy, Utah clinic receives a comprehensive cardiovascular workup before therapy starts. This is not standard medical practice. Most clinics prescribing hormone therapy do a basic lipid panel and a blood pressure reading. We do more because cardiovascular risk is the single biggest reason to either use or avoid hormone therapy, and you cannot make that decision without the data. Our Female Balance and Beauty program is built around individualized assessment and ongoing monitoring rather than one-size-fits-all dosing.
The pre-therapy cardiovascular workup at our clinic typically includes a 10-year ASCVD risk calculation (the American Heart Association / American College of Cardiology calculator), an advanced lipid panel that goes beyond total cholesterol to measure LDL particle number and size, inflammatory markers including hs-CRP, fasting glucose and insulin to assess insulin sensitivity, and a baseline DEXA scan to measure visceral adipose tissue directly. We also review family history of cardiovascular disease, personal history of clotting, and any other relevant risk factors. Once we have all of that, we know whether hormone therapy is appropriate and, if so, which formulation and delivery route will minimize her individual risk.
For women with low cardiovascular risk who are within ten years of menopause onset, the answer is usually yes, hormone therapy is appropriate and likely cardioprotective. For women with intermediate risk, we often favor transdermal estradiol over oral estrogen because the transdermal route avoids first-pass liver metabolism and is associated with lower thrombotic risk. For women with established cardiovascular disease or significantly elevated 10-year risk, we may recommend against systemic hormone therapy and focus on other interventions. The decision is individual. The data tells us what to do.
A patient story from our Sandy office (details adjusted to protect privacy): the same postmenopausal woman in her early fifties whose journey we have referenced in our companion articles on GLP-1 weight loss and postmenopausal bone density also moved meaningfully on her cardiovascular risk profile. At her baseline assessment, she carried elevated cardiovascular risk markers consistent with postmenopausal metabolic shift: high body mass index in the obesity range, elevated waist circumference, and the visceral fat distribution pattern typical of women in early menopause without hormone optimization. Over the year and a half of comprehensive care, her body composition shifted dramatically: more than 55 pounds of fat loss, BMI returning to the normal range, visceral fat substantially reduced. The cardiovascular benefit of those changes is well documented in the literature. Combined with hormone optimization started inside the window of opportunity, this is exactly the trajectory the timing hypothesis predicts. This is one example, not a guaranteed outcome, but it is what comprehensive care looks like when the protocol is built around the right time horizon.
5. Questions to ask before menopause hits
If you are perimenopausal or recently postmenopausal, these are the cardiovascular questions that matter. Ask them now, while the window is open.
Have I had a comprehensive cardiovascular risk assessment recently?
A standard physical with a basic lipid panel is not a cardiovascular risk assessment. A real one includes ASCVD calculator scoring, advanced lipid testing (particle number and size, not just total LDL), inflammatory markers like hs-CRP, fasting insulin and glucose, blood pressure trends over time, and ideally a visceral fat measurement. If your provider has not done this, you are working with incomplete data.
What is my visceral fat measurement?
Visceral fat is the metabolically dangerous fat around your abdominal organs, and it accumulates rapidly during the menopause transition even when total body weight stays the same. A DEXA scan can measure it directly. A bathroom scale cannot. If you have never had this measured, you do not know your actual cardiovascular risk profile.
Am I a candidate for hormone therapy from a cardiovascular perspective?
Most healthy women under 60, or within ten years of menopause onset, with a 10-year ASCVD risk under 10 percent, are candidates for hormone therapy. Specific contraindications (established cardiovascular disease, recent thrombotic event, certain clotting disorders) are well defined. Bioidentical hormone optimization is something we evaluate individually for every patient, based on her labs, risk profile, family history, and personal preferences.
If hormone therapy is appropriate, oral or transdermal?
Oral estrogen passes through the liver before reaching circulation, which can affect clotting factors and triglycerides. Transdermal estradiol is absorbed through the skin and bypasses first-pass liver metabolism. For women with any elevated cardiovascular or thrombotic risk, the transdermal route is generally preferred. Most clinics do not have this conversation in detail. They should.
What is my long-term monitoring plan?
Cardiovascular risk is not a one-time assessment. Lipid panels, blood pressure, inflammatory markers, and body composition should be tracked over time. If your provider does not have a clear plan for follow-up monitoring, you have a treatment plan without a feedback loop.
Key insight: A real cardiovascular evaluation in midlife answers five questions. Comprehensive risk assessment with ASCVD calculator and advanced lipids. Visceral fat measurement. Candidacy for hormone therapy. Formulation and delivery route. Long-term monitoring. If any of those five are missing, you are not getting comprehensive care.
6. Why we wrote this
We wrote this article because the consequences of the past two decades of cardiovascular misinformation have been enormous. An entire generation of women was steered away from a therapy that, when started in the right window, would have measurably reduced their risk of dying of heart disease. That is not a small thing. It is one of the largest unforced errors in modern preventive medicine.
Most women still do not know that heart disease is the leading cause of death for women. Most women still do not know that menopause itself drives a measurable increase in cardiovascular risk. Most women have never had a comprehensive cardiovascular evaluation in midlife. Most women have never had their visceral fat measured. Most women whose providers steered them away from hormone therapy in their fifties are now in their sixties and seventies, outside the window where the cardioprotective benefit applies, and dealing with the cardiovascular consequences nobody warned them about.
The FDA’s November 2025 decision was a correction, but it does not by itself fix the awareness gap. The conversation has to happen in clinics, one woman at a time. In our Sandy office, this is the conversation we are having every day with women coming through our doors. If you are in the Salt Lake City area and you want to know what is actually happening to your cardiovascular health, we would like to help.
The Bottom Line
Heart disease kills more American women than every cancer combined, and the risk accelerates sharply at menopause as estrogen-mediated cardiovascular protection is lost. For the past two decades, women have been steered away from hormone therapy based on the initial Women’s Health Initiative findings, which were later understood to apply primarily to older women started long after menopause. The timing hypothesis, supported by the ELITE and KEEPS trials and stratified WHI re-analyses, establishes that hormone therapy initiated within ten years of menopause onset reduces cardiovascular risk for most women. The FDA’s November 2025 removal of black box warnings on cardiovascular disease, breast cancer, and probable dementia reflects this evidence. A complete midlife cardiovascular evaluation includes ASCVD risk calculation, advanced lipid panel, inflammatory markers, visceral fat measurement, and individualized hormone therapy decision-making. The window of opportunity is real. It is also closing for every woman who does not act inside it.
Frequently Asked Questions
Does hormone therapy increase heart disease risk?
It depends on when therapy is started. Hormone therapy initiated within ten years of menopause onset, or before age 60, in women without established cardiovascular disease, is associated with reduced cardiovascular risk. Hormone therapy initiated more than ten years after menopause onset, or after age 60, can increase cardiovascular risk. This is called the timing hypothesis and is now well established by multiple randomized trials including ELITE and KEEPS, plus stratified re-analyses of the Women’s Health Initiative. The FDA’s November 2025 black box warning removal reflects this updated understanding.
What is the timing hypothesis?
The timing hypothesis states that the cardiovascular effects of hormone therapy depend on when treatment is initiated relative to menopause onset. In early postmenopause, before significant atherosclerotic plaque has formed, hormone therapy supports endothelial function and reduces cardiovascular risk. In late postmenopause, when plaque is already established, hormone therapy can destabilize existing disease and increase cardiovascular events. The ELITE trial, published in the New England Journal of Medicine, demonstrated this directly: women started on estradiol within six years of menopause showed slowed atherosclerosis progression, while women started more than ten years after menopause showed no benefit.
When is too late to start hormone therapy for cardiovascular protection?
Most clinical guidelines, including the American College of Obstetricians and Gynecologists position and the Endocrine Society guidelines, recommend hormone therapy for women under age 60 or within ten years of menopause onset for symptom management and cardiovascular protection. Beyond that window, the cardiovascular benefit drops and risks may exceed benefits. A woman more than ten years past menopause with a 10-year ASCVD risk above 10 percent is generally not a candidate for systemic hormone therapy on cardiovascular grounds. This does not mean nothing can be done. Statins, blood pressure management, weight management, and lifestyle interventions all retain effectiveness regardless of timing.
Why did the FDA reverse its position on hormone therapy?
On November 10, 2025, the FDA announced removal of the longstanding black box warnings on cardiovascular disease, breast cancer, and probable dementia from menopause hormone therapy products. The agency cited a comprehensive scientific review, an expert panel, and a public comment period. FDA Commissioner Marty Makary stated in JAMA that the original warnings were based on outdated science and had discouraged appropriate use of hormone therapy. The endometrial cancer warning for estrogen-alone products remains in place. The reversal reflects more than two decades of accumulated evidence that the original WHI findings, which had been generalized to all women, primarily applied to older women started long after menopause.
How does menopause itself affect cardiovascular risk?
The menopause transition causes multiple measurable cardiovascular changes simultaneously: LDL cholesterol rises, HDL cholesterol falls or shifts toward less protective subtypes, triglycerides increase, blood pressure tends to climb, insulin sensitivity declines, visceral fat accumulates, and inflammatory markers rise. The American Heart Association’s 2020 scientific statement explicitly identifies menopause itself as contributing to the increase in coronary heart disease risk that women experience in midlife. This is not just aging. It is a specific physiological shift with specific cardiovascular consequences.
What is visceral fat and why does it matter?
Visceral fat is the metabolically active fat that accumulates around abdominal organs. It is different from subcutaneous fat (the fat just under the skin) in that it produces inflammatory cytokines, contributes to insulin resistance, and is independently associated with cardiovascular disease, type 2 diabetes, and all-cause mortality. The menopause transition shifts a woman’s fat distribution from predominantly subcutaneous to predominantly visceral, even when her total body weight stays the same. A bathroom scale cannot measure visceral fat. A DEXA scan can. At Revitalize Medical Solutions in Sandy, Utah, baseline visceral fat measurement is part of our cardiovascular evaluation. The connection between visceral fat, GLP-1 medications, and hormone optimization is covered in detail in our companion article on GLP-1 medications and menopause.
Is BHRT different from conventional HRT for heart health?
The cardiovascular mechanism is the same. Estradiol protects the endothelium and supports favorable lipid metabolism whether it is delivered as a bioidentical preparation or a conventional synthetic formulation. What changes with bioidentical hormone therapy is the ability to dose more precisely to individual labs, the side effect profile, and the route of administration. For cardiovascular patients specifically, route of administration matters. Transdermal bioidentical estradiol avoids the first-pass liver effects that can elevate clotting factors and triglycerides with oral estrogen. Many of our higher-risk cardiovascular patients are good candidates for transdermal BHRT specifically because of this delivery profile.
What testing should I have before starting hormone therapy?
A complete pre-therapy workup includes a comprehensive lipid panel (ideally with LDL particle number and size), inflammatory markers including hs-CRP, fasting glucose and insulin, blood pressure trends, 10-year ASCVD risk calculation using the AHA/ACC calculator, body composition measurement (DEXA preferred), and a thorough family and personal history of cardiovascular disease and clotting disorders. For women with significant family history of breast cancer or other estrogen-sensitive conditions, additional screening may be appropriate. The goal is to know the full risk picture before starting therapy, not to discover problems after.
Can hormone therapy reverse existing heart disease?
No, and that is not what hormone therapy is for. In women with established cardiovascular disease, hormone therapy can actually destabilize existing atherosclerotic plaque and increase the risk of acute events. This is one of the main reasons the timing hypothesis matters: hormone therapy is preventive, not therapeutic. It works by supporting healthy endothelial function and metabolic regulation in women who do not yet have significant atherosclerosis. In women with established disease, the appropriate interventions are statins, blood pressure management, weight optimization, and standard secondary prevention strategies. We do not use hormone therapy in those patients.
How does Revitalize approach cardiovascular evaluation for hormone therapy patients?
Four principles. First, comprehensive baseline cardiovascular assessment before any hormone therapy decision, including DEXA-measured visceral fat, advanced lipid panel, inflammatory markers, and ASCVD risk calculation. Second, individualized formulation and delivery route based on her specific risk profile, with transdermal preferred for higher cardiovascular risk patients. Third, ongoing monitoring with follow-up labs and DEXA scans to confirm the protocol is working. Fourth, integration with the rest of her care including weight management, nutrition, and strength training. For more about how we work with patients, see our patient FAQs.
When was your last comprehensive cardiovascular evaluation?
Comprehensive cardiovascular workup, individually dosed BHRT, DEXA-measured visceral fat, and a structured monitoring plan. At our Sandy, Utah clinic. The full program, not just a prescription.
SCHEDULE A FREE CONSULTATION AT OUR SANDY, UTAH CLINIC →
References
Hodis HN, Mack WJ, Henderson VW, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol (ELITE Trial). New England Journal of Medicine. 2016;374:1221-1231. https://www.nejm.org/doi/full/10.1056/NEJMoa1505241
Kronos Early Estrogen Prevention Study (KEEPS). Lessons from KEEPS. International Menopause Society. https://www.imsociety.org/2021/06/21/lessons-from-keeps-the-kronos-early-estrogen-prevention-study/
El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention. A Scientific Statement From the American Heart Association. Circulation. 2020. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000912
Makary MA, Nguyen CP, Hoeg TB, Tidmarsh GF. Updated Labeling for Menopausal Hormone Therapy. JAMA. 2025 Nov 10. doi: 10.1001/jama.2025.22259.
FDA. Requests Labeling Changes Related to Safety Information to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies. November 10, 2025.
Khalifey HT, Mahereen R, Adwan R, et al. The impact of hormone replacement therapy on cardiovascular health in postmenopausal women: a narrative review. Frontiers in Reproductive Health. 2026. https://www.frontiersin.org/journals/reproductive-health/articles/10.3389/frph.2026.1745210/full
Cardiovascular Risk Associated with Menopause and Menopause Hormone Therapy: A Review and Contemporary Approach to Risk Assessment. PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12511246/
Miao X, Wu L, Wang K, et al. Risk factors for coronary atherosclerotic heart disease in postmenopausal women: a meta-analysis. Frontiers in Cardiovascular Medicine. January 2025. https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1434149/full
American Heart Association. Heart Health Declines Rapidly After Menopause. ACC Annual Scientific Session 2024 findings. https://www.acc.org/About-ACC/Press-Releases/2024/04/01/21/39/heart-health-declines-rapidly-after-menopause
Reviewed by Nicole Kelly, PA-C · Medical Director, Revitalize Medical Solutions · Sandy, Utah · Contributing voice from Cale Bybee, COO and Utah-licensed Bone Densitometry Equipment Operator · All clinical claims verified prior to publication · Patient case study presented with details adjusted to protect privacy · Document version 1.0 · Third article in the Revitalize flagship trilogy (GLP-1, Bone Density, Cardiovascular)
